What is PathoQuest?
PathoQuest specializes in the development and commercialization of biosafety assays that leverage next-generation sequencing (NGS) technology. By providing high-precision genetic analysis and quality control services, the company enables biopharmaceutical developers to ensure the safety and regulatory compliance of their innovative therapies. Positioned at the intersection of biotechnology and digital diagnostics, PathoQuest serves as a critical partner for both emerging biotech firms and established global pharmaceutical entities. Their platform is engineered to replace legacy, animal-based testing protocols with faster, more accurate, and ethically sound digital solutions, thereby streamlining the path from laboratory development to clinical application.
How much funding has PathoQuest raised?
PathoQuest has raised a total of $13.8M across 2 funding rounds:
Unspecified
$5M
Other Financing Round
$8.8M
Unspecified (2013): $5M with participation from Idinvest Partners, Kurma Partners, and Aurinvest
Other Financing Round (2019): $8.8M led by Norgine, Kurma Partners, Charles River Labs, Idinvest Partners, investiere, and French Public Program Investissement D'Avenir
Key Investors in PathoQuest
Idinvest Partners
Idinvest Partners is a mid-market private equity firm that finances and supports entrepreneurs across various stages of business development.
Kurma Partners
Kurma Partners is a prominent European venture capital firm specializing in healthcare and biotechnology, focusing on transforming scientific discoveries into advanced medical solutions.
Aurinvest
Aurinvest is a venture capital fund managed by entrepreneurs that invests primarily in high-growth technology and life science companies.
What's next for PathoQuest?
With the support of its latest strategic financing, PathoQuest is well-positioned to scale its operational capacity and expand its footprint in the international biopharma market. The company is expected to prioritize the enhancement of its NGS platform to meet the increasingly stringent requirements of global regulatory bodies. By focusing on the integration of its services into the early-stage development pipelines of major pharmaceutical companies, PathoQuest aims to become the industry standard for biotherapeutic safety. Future growth will likely center on deepening its technological moat through continued R&D investment and strategic partnerships with key players in the life sciences sector, ensuring that their quality control solutions remain at the forefront of the rapidly evolving biopharmaceutical industry.
See full PathoQuest company page
